Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agenus Inc (NQ: AGEN )

3.580 +0.440 (+14.01%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Agenus Inc

< Previous 1 2 3 4 5 Next >
Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development
Agenus secures a $22M mortgage and announces a strategic realignment to focus on botensilimab/balstilimab in MSS colorectal cancer. 
Via Benzinga
Agenus (AGEN) Q3 2024 Earnings Call Transcript
AGEN earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Earnings Scheduled For November 12, 2024
Via Benzinga
Insights Ahead: Agenus's Quarterly Earnings
Via Benzinga
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The study showed a non-inferior immune response and good safety profiles. The... 
Via Benzinga
Exposures Product Safety
Agenus (AGEN) Q2 2024 Earnings Call Transcript
AGEN earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Up 40%: Is This Red-Hot Growth Stock Still a Buy?
This small-cap biotech stock is surging. Time to buy? 
Via The Motley Fool
AGEN Stock Earnings: Agenus Misses EPS, Misses Revenue for Q2 2024
AGEN stock results show that Agenus missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
Agenus reports that Bristol Myers Squibb (NYSE: BMY) is ending their 2021 agreement, returning the TIGIT bispecific antibody AGEN1777. This decision is part of Bristol Myers' broader pipeline strategy... 
Via Benzinga
Agenus Faces Regulatory and Financial Challenges: Analyst Downgrades Stock Pending Trial Clarity
Agenus faces a setback as the FDA advises against accelerated approval for its immunotherapy combination, botensilimab and balstilimab, for relapsed/refractory microsatellite-stable colorectal cancer.... 
Via Benzinga
Exposures Product Safety
Nasdaq Down Over 100 Points; Abbott Laboratories Earnings Beat Views
Via Benzinga
Topics Earnings
Exposures Financial
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Dow Dips 250 Points; US Weekly Jobless Claims Surge
Via Benzinga
Topics Stocks
Exposures US Equities
WBD Stock Pops as Warner Bros. Considers Streaming Spinoff
Warner Bros. stock is rising on Thursday as reports about a potential spinoff of its streaming division embolden WBD investors. 
Via InvestorPlace
Agenus Loses More Than 50% Value On Thursday - Here's Why
Agenus shares drop amid FDA's feedback on its immunotherapy combo botensilimab and balstilimab for colorectal cancer. The FDA advised against accelerated approval, citing concerns about survival... 
Via Benzinga
Exposures Product Safety
Why Is NKGen Biotech (NKGN) Stock Up 18% Today?
NKGen Biotech stock is up Thursday as NKGN holders react to plans for a presentation at the Alzheimer’s Association International Conference. 
Via InvestorPlace
Why Is Agenus (AGEN) Stock Down 55% Today?
Agenus stock is down on Thursday after the company provided AGEN investors with an update on a Phase 2 clinical trial meeting. 
Via InvestorPlace
US Stocks Edge Higher; D.R. Horton Posts Upbeat Earnings
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Saia, Annexon, Core Scientific And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
Though risky, investors who buy biotech stocks watch their portfolios skyrocket when their drugs work as intended. 
Via InvestorPlace
7 Biotech Stocks to Put on Your Breakthrough Radar
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. 
Via InvestorPlace
3 Magnificent Growth Stocks to Buy Hand Over Fist
Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst. 
Via The Motley Fool
Topics Economy
Exposures Interest Rates
Agenus (AGEN) Q1 2024 Earnings Call Transcript
AGEN earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
AGEN Stock Earnings: Agenus Misses EPS, Misses Revenue for Q1 2024
AGEN stock results show that Agenus missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Top 2 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings. 
Via Benzinga
Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom
The latest Phase 1 trial results of Agenus' botensilimab and balstilimab (BOT/BAL) combination therapy for metastatic CRC showcase promising clinical activity. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.